Novo Nordisk: Number of Employees 2010-2023 | NVO

Interactive chart of Novo Nordisk (NVO) annual worldwide employee count from 2010 to 2023.
  • Novo Nordisk total number of employees in 2023 was 63,370, a 14.83% increase from 2022.
  • Novo Nordisk total number of employees in 2022 was 55,185, a 22.63% increase from 2021.
  • Novo Nordisk total number of employees in 2021 was 45,000, a 0.71% decline from 2020.
  • Novo Nordisk total number of employees in 2020 was 45,323, a 4.77% increase from 2019.
Novo Nordisk Annual Employee Count
2023 63,370
2022 55,185
2021 45,000
2020 45,323
2019 43,258
2018 43,202
2017 42,076
2016 41,971
2015 41,000
2014 41,450
2013 38,000
2012 33,061
2011 32,000
2010 30,000
2009 29,154
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $550.665B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67